Descovy 200 mg/25 mg film-coated tablets
Sponsors
Gilead Sciences Inc., Fundacion Seimc Gesida, Fundacion Seimc Gesida, Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Stichting Radboud universitair medisch centrum, Fondazione Penta Ets
Conditions
HIV InfectionsHIV-infectedHuman Immunodeficiency VirusMetabolic liver disease in HIV-infected peoplePre-Exposure Prophylaxis of HIV-1 Infection
Phase 2
Phase 3
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection.
Active, not recruitingCTIS2022-501763-40-00
Start: 2016-12-13Target: 2090Updated: 2025-08-22
A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old
Active, not recruitingCTIS2024-520388-15-00
Start: 2023-06-30Target: 6Updated: 2025-08-12
Phase 4
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
CompletedCTIS2022-503110-23-00
Start: 2023-05-05End: 2025-07-07Target: 75Updated: 2023-08-28
Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study)
RecruitingCTIS2023-504952-87-00
Start: 2025-01-13Target: 50Updated: 2024-09-18
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
CompletedCTIS2024-515487-31-00
End: 2025-12-12Target: 163Updated: 2024-10-22